{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-041975","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.048267+00:00","generated_at":"2026-05-16T03:54:38.855392+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"IN8bio appoints COO Kate Rochlin as President, effective immediately","bullets":["Kate Rochlin, current COO, assumes additional role of President effective Feb. 4, 2026.","Dr. Rochlin will continue serving as Chief Operating Officer of IN8bio.","Appointment made by Board on Feb. 4, 2026; no other executive changes.","No family relationships or transactions requiring disclosure under Regulation S-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-041975","json":"https://secwatch.observer/filing/0001193125-26-041975.json","markdown":"https://secwatch.observer/filing/0001193125-26-041975.md","text":"https://secwatch.observer/filing/0001193125-26-041975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526041975/0001193125-26-041975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526041975/d50284d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:54:38.855392+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}